Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 903, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2021.174150
Keywords
Extracellular signal-regulated kinases 1; 2; Dopamine D2 receptor; Seizures; GIZH-298; Valproic acid
Categories
Funding
- RSF by Russian Science Foundation [19-14-00167]
- State Program for Fundamental Scientific Research [0521-2019-0007]
- Russian Science Foundation [19-14-00167] Funding Source: Russian Science Foundation
Ask authors/readers for more resources
The study suggests that GIZH-298 may alleviate seizures in mice by modulating dopamine D2 receptors and ERK1/2 kinase activity.
Inhibition of the activity of extracellular signal-regulated kinases (ERK1/2) induced by the activation of the dopamine D2 receptor signalling cascade may be a promising pharmacological target. The aim of this work was to study the involvement of ERK1/2 and dopamine D2 receptor in the mechanism of the anticonvulsant action of valproic acid (VA) and a new benzoylpyridine oxime derivative (GIZH-298), which showed antiepileptic activity in different models of epilepsy. We showed that subchronic exposure to maximal electroshock seizures (MES) for 5 days reduced the density of dopamine D2 receptors in the striatum of mice. GIZH-298 counteracted the decrease in the number of dopamine D2 receptors associated with MES and increased the number of ligand binding sites of dopamine D2 receptors in mice without MES. The affinity of dopamine D2 receptors to the ligand was not changed by GIZH-298. MES caused an increase in ERK1/2 and synapsin I phosphorylation in the striatum while GIZH-298, similar to VA, reduced the levels of both phospho-ERK1/2 and phosphosynapsin I after MES, which correlated with the decrease in the intensity of seizure in mice. In addition, GIZH-298 suppressed ERK1/2 phosphorylation in SH-SY5Y human neuroblastoma cells at therapeutic concentrations, while VA inhibited ERK1/2 phosphorylation in vivo but not in vitro. The data obtained expand the understanding of the mechanisms of action of VA and GIZH-298, which involve regulating the activity of ERK1/2 kinases, probably by modulating dopamine D2 receptors in limbic structures, as well as (in the case of GIZH-298) directly inhibiting of the ERK1/2 cascade.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available